New England Biolabs
SomaLogic Scores One-Time, $21.2M Licensing Royalty in Q3, Raises FY 2022 Revenue Guidance
The Boulder, Colorado-based proteomics assay maker beat Wall Street estimates on the top and bottom lines in Q3, driven by higher product revenues.
The tool combines geographical data on viral mutations with an easy-to-use interface to check whether primers may be affected.
Many Initiatives Turning to RT-LAMP as Alternative to PCR for Rapid COVID-19 Screening Assays
Grassroots efforts are leading the way in a number of commercial and non-commercial screening tests in development.
Avacta Licenses Affimer Tech to New England Biolabs
New England Biolabs is using Avacta's affimers with a development-stage research and diagnostic assay that could launch as early as next year.
New England Biolabs, TTP Partner to Provide MDx Development Services
The services will couple NEB's reagents and expertise in enzyme development and manufacturing with TTP's Desktop Biology product development and engineering know-how.